LAURUSLABSLaurus Labs Limited Forensic Risk Analysis

Pharmaceuticals
Risk ClassStable
Market Cap₹57,657 Cr
Primary DriverGrowth Sustainability
Flagium AI Risk Score
Stable structural profile. Financial profile appears resilient.
5 / 100
+5 QoQ
Early Deterioration
Sentinel Insight

Financial profile remains stable for now. Weakness is detected in growth sustainability. No immediate concerns are visible. Risk is increasing at a faster pace.

6.1th %ile (Sector)Accel: +1 Qtrs
Updated2026-06-02
Market View
₹1,382.6▼0.42%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Growth Sustainability
+10.0 pts
Balance Sheet Stress
+6.4 pts
Stability Adjustment
-11.0 pts
Final Composite Risk5 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 4 → 5 over 13 quarters.

Expected Direction
⚠ Watch
Primary Deterioration Drivers
  • Inventory Stress
  • Working Capital Expansion
  • Low Interest Coverage
What to Watch Next Quarter
  • Operating profit margins
  • Inventory turnover
  • Working capital efficiency

Active Risk Objects (6)

CriticalHigh
Low Interest Coverage
💧 Liquidity & CoverageQuarterlyActive for 5 Qtrs
More Detail
Impact Weight8/15
MomentumDecaying
Last SignalQ2 FY2025
LAURUSLABS: Low Interest Coverage Ratio of 1.43x in FY2025 Q2 (Threshold: 2.5x).

"The ability to cover interest is strengthening as earnings improve or debt is retired."

Inventory Stress
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight15/15
MomentumAccelerating
Last SignalQ4 FY2026
Inventory growth (20.9%) significantly outpaced revenue growth (2.5%).

"Stock is piling up in the warehouse. Inventory turnover is slowing down dangerously."

Profit Collapse
📊 Earnings QualityQuarterlyActive for 4 Qtrs
More Detail
Impact Weight8/15
MomentumDecaying
Last SignalQ1 FY2025
LAURUSLABS: Net Profit collapsed by 52.7% from FY2024 Q1 to FY2025 Q1.

"Earnings quality is stabilizing. The reliance on non-operational items is receding."

Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 1 Years
More Detail
Impact Weight10/15
MomentumAccelerating
Last SignalQ4 FY2026
Working capital expansion detected: Receivable days increased by 4.7%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Capex Efficiency Stress
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight8/15
MomentumDecaying
Last SignalQ2 FY2025
Aggressive Capex (21.3%) amidst slow revenue growth (0.2%).

"Earnings quality is stabilizing. The reliance on non-operational items is receding."

Revenue-Debt Divergence
🏛️ Solvency & LeverageAnnualActive for 1 Years
More Detail
Impact Weight6/15
MomentumDecaying
Last SignalFY2024
LAURUSLABS: Revenue fell 16.2% while Debt rose 27.1% in 2024 vs 2023.

"Debt servicing metrics have improved recently. The company is actively deleveraging."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)5.087.70✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+61.0+47.0✅ RESILIENT
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹1,382.6(-0.42%)
1M Divergence+23.44%
1 Week+0.63%
1 Month+25.71%
6 Months+36.55%
1 Year+126.66%
2 Year+231.34%
3 Year+301.97%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in growth sustainability remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. Strategic vigilance is advised as structural decay is accelerating.

LAURUSLABS • MARKET STRUCTURE

Stage 2 — Advancing

The company is in a growth phase. Institutional sentiment is highly positive, supported by strong fundamentals and sustained risk reduction.

Stage Transition Prob.97%
Trend QualityStrong
Phase Progression
Phase Progression Score90%
Readiness LabelHigh (Phase Transition Imminent)
Probability of Advancing97%
CoinTree Momentum
Composite Z-Score+0.9799σ
Improving momentum strength
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#253 of 2716
Top 9.32% in momentum strength
Timeframe Sparklines
1W+0.6%
1M+25.7%
6M+36.5%
Weinstein Indicators
150 DMA₹1,067.42
200 DMA₹1,019.54
150 DMA Slope+5.7439%Rising
Relative Strength+42.04%Leading
Relative Turnover (RTR)1.4258
ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

This company appears relatively stable compared to the Sector Mean (19).
ABBOTINDIAABBOTINDIA
0 Risk
Sector %ile0th
Delta0
Active Flags0
Accel+0
Governance

Stable

LAURUSLABSLaurus Labs Limited
5 Risk
Sector %ile6th
Delta+5
Active Flags6
Accel+1
Growth Sustainability

Stable

AARTIDRUGSAarti Drugs Limited
19 Risk
Sector %ile51th
Delta-5
Active Flags11
Accel+0
Competitive Position

Stable

AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
23 Risk
Sector %ile63th
Delta-5
Active Flags20
Accel+0
Balance Sheet Stress

Watch

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
6.868th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
00th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Inventory Stress

2026

Working Capital Expansion

2025

Inventory Stress

2025

Capex Efficiency Stress

2024

Capex Efficiency Stress

2024

Revenue-Debt Divergence

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY20266,8688901,6242,397
FY20255,6293586022,693
FY20245,0671626662,507
FY20236,0477939941,972